Gothenburg, February 24, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company that develops next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that the company’s Chief Scientific Officer (CSO) and co-founder, Professor Magnus Essand, will present at SWECARNET’s Educational Day on April 27th, 2022.
SWECARNET, Sweden’s network for clinical use of CAR T-cells, will hold an Educational Day on April 27th, 2022, where Elicera’s CSO, Professor Magnus Essand, will hold a presentation on the topic: What will reseach bring in the future?
More information and the program can be found here: https://atmpsweden.se/events/swecarnet-utbildningsdag-2022/
Registration can be done here: https://www.eventbrite.com/e/swecarnet-utbildningsdag-biljetter-265001345157
SWECARNET is Sweden’s network for clinical use of CAR T-cells and was established in 2019 by the SDP5 Swelife-ATMPproject of the same name. Coordinated by the Centre for Cell therapy and Allogeneic Stem cell Transplantation (CAST) at Karolinska University Hospital, the network brings together those in Sweden developing, implementing or treating patients with Chimeric antigen receptor T (CAR T) cells
Network partners: Uppsala Universitet, Skånes Universitetssjukhus, Sahlgrenska Universitetssjukhuset, Karolinska Institutet, Karolinska Universitetssjukhuset, Novartis Sverige AB, Celgene AB/BMS, Gilead Science Sweden AB, Jansen-Cilag AB and Läkemedelsindustriföreningen
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next generation immuno-oncology treatments based on enhanced oncolytic viruses and CAR T-cells. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T-cells in development and activate killer T-cells against cancer. The company’s share (ELIC) is traded on Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: email@example.com, tel: +468-503 000 50.